Insider Selling: Health Catalyst, Inc. (NASDAQ:HCAT) COO Sells 16,902 Shares of Stock

Health Catalyst, Inc. (NASDAQ:HCAT) COO Daniel Lesueur sold 16,902 shares of the business’s stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $4.52, for a total value of $76,397.04. Following the completion of the sale, the chief operating officer now directly owns 216,250 shares of the company’s stock, valued at $977,450. The trade was a 7.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Daniel Lesueur also recently made the following trade(s):

• On Wednesday, February 5th, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The stock was sold at an average price of $5.76, for a total value of $30,003.84.
• On Monday, January 6th, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The shares were sold at an average price of $7.51, for a total value of $39,119.59.

Health Catalyst Price Performance

Shares of NASDAQ:HCAT traded down $0.32 during trading on Monday, reaching $3.97. The stock had a trading volume of 1,010,415 shares, compared to its average volume of 898,193. The business’s 50-day moving average price is $5.73 and its 200 day moving average price is $7.16. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41. The stock has a market capitalization of $278.74 million, a PE ratio of -2.94 and a beta of 1.41. Health Catalyst, Inc. has a 52 week low of $3.76 and a 52 week high of $9.24.

Wall Street Analyst Weigh In

HCAT has been the subject of several research analyst reports. Piper Sandler dropped their price target on shares of Health Catalyst from $12.00 to $8.00 and set an “overweight” rating for the company in a research report on Tuesday, February 11th. KeyCorp raised shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price target for the company in a report on Wednesday, January 8th. Royal Bank of Canada cut their target price on Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research report on Thursday, February 27th. Canaccord Genuity Group reduced their target price on Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, January 21st. Finally, Citigroup dropped their target price on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a report on Friday, January 10th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $9.27.

Institutional Investors Weigh In On Health Catalyst

A number of hedge funds have recently added to or reduced their stakes in HCAT. Quantbot Technologies LP acquired a new position in Health Catalyst during the 4th quarter valued at about $29,000. Group One Trading LLC grew its holdings in shares of Health Catalyst by 107.6% in the 4th quarter. Group One Trading LLC now owns 4,360 shares of the company’s stock valued at $31,000 after buying an additional 2,260 shares during the period. Quest Partners LLC bought a new stake in shares of Health Catalyst in the 3rd quarter valued at $34,000. Aquatic Capital Management LLC bought a new stake in shares of Health Catalyst in the 4th quarter valued at $63,000. Finally, Stoneridge Investment Partners LLC acquired a new position in Health Catalyst in the fourth quarter valued at about $77,000. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.